Can hepatocytes serve as ‘activated’ immunomodulating cells in the immune response?

doi:10.1016/S0168-8278(05)80121-7

Journal of Hepatology

Volume 16, Issues 1–2, 1992, Pages 228-240

https://doi.org/10.1016/S0168-8278(05)80121-7 Get rights and content

During the last few years, there has been a growing evidence that hepatocytes are not merely ‘passive’ target cells for immunological attack by effector T-cells, but may play a more ‘active’ role in the initiation and perpetuation of the immune response. Immune modulators released by inflammatory cells at the site of inflammation, as well as the eliciting antigen itself, are able to modulate the phenotype of hepatocytes. This would result in abnormal cytokine production and/or cytokine/receptor expression, as well as active synthesis and display of surface immune ‘activation’ markers and adhesion molecules, which act as co-stimulatory signals for T-cell activation. These accessory functions involve multiple molecular pathways of cell-cell interactions, which in turn will enable hepatocytes to play a role as ‘accessory’ cells in both the afferent and efferent arms of the cell-mediated immune response.

References (138)

WeaverCT et al.
The costimulatory function of antigen-presenting cells
Immunol Today
(1990)
BarkerJNWN et al.
Keratinocytes as initiators of inflammation
Lancet
(1991)
ColucciG et al.
In situ characterization by monoclonal antibodies of the mononuclear cell infiltrate in chronic active hepatitis
Gastroenterology
(1983)
SandersME et al.
Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets
Immunol Today
(1988)
ThieleDL et al.
The role of cell surface recognition structures in the initiation of MHC-unrestricted ‘promiscuous’ killing by T-cells
Immunol Today
(1989)
MaliziaG et al.
Expression of leukocyte adhesion molecules in the liver of patients with chronic hepatitis B virus infection
Gastroenterology
(1991)
AdamsDH et al.
Intercellular adhesion molecule 1 on liver allografts during rejection
Lancet
(1989)
SteinhoffG et al.
Expression of adhesion molecules on lymphocytes/monocytes and hepatocytes in human liver grafts
Hum Immunol
(1990)
VolpesR et al.
Adhesive molecules in liver disease. Immunohistochemical distribution of thrombospondin receptors in chronic HBV infection
J Hepatol
(1990)
StauntonDE et al.
Primary structure of ICAM-1 demonstrates interaction between members of the Immunoglobulin and Integrin supergene families
Cell
(1988)

MarlinSD et al.

Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen-1 (LFA-1)

Cell

(1987)

MakgobaMW et al.

The CD2-LFA-3 and LFA-1-ICAM-1 pathways: relevance to T-cell recognition

Immunol Today

(1989)

SingerKH et al.

Epidermal keratinocytes express the adhesion molecule intercellular adhesion molecule-1 in inflammatory dermatoses

J Invest Dermatol

(1989)

GriffithsCEM et al.

Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor

J Am Acad Dermatol

(1989)

FrohmanEM et al.

The induction of intercellular adhesion molecule-1 (ICAM-1) expression on human fetal astrocytes by interferon-γ, tumor necrosis factor-α, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation

J Neuroimmunol

(1989)

TandonNN et al.

Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion

J Biol Chem

(1989)

LisbyS et al.

Expression of OKM5 antigen on epidermal cells in mycosis fungoides plaque stage

J Invest Dermatol

(1988)

BaadsgaardO et al.

UM4D4 + (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions

J Invest Dermatol

(1990)

HaynesBF et al.

CD44 — A molecule involved in leukocyte adherence and T-cell activation

Immunol Today

(1989)

GeppertTD et al.

Antigen presentation at the inflammatory site

Crit Rev Immunol

(1989)

UnanueER et al.

The basis for the immunoregulatory role of macrophages and other accessory cells

Science

(1987)

GeppertTD et al.

Accessory cell signals involved in T-cell activation

Immunol Rev

(1990)

AustynJM

Lymphoid dendritic cells

Immunology

(1987)

LondeiM et al.

Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells

Nature

(1985)

GerberMA

Immunopathology of chronic hepatitis

DesmetVJ

Immunopathology of chronic viral hepatitis

Hepato-Gastroenterology

(1991)

SiL et al.

Studies of lymphocyte subpopulations in the liver tissue and blood of patients with chronic active hepatitis

J Clin Immunol

(1983)

MontanoL et al.

An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease

Hepatology

(1983)

EgginkHF et al.

Cellular and humoral immune reactions in chronic active liver disease. II. Lymphocyte subsets and viral antigens in liver biopsies of patients with acute and chronic hepatitis B

Clin Exp Immunol

(1984)

VolpesR et al.

Memory T cells represent the predominant lymphocyte subset in acute and chronic liver inflammation

Hepatology

(1991)

SandersME et al.

Human memory T-lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2 and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production

J Immunol

(1988)

YangP-M et al.

Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic Type B hepatitis, with special emphasis on the activation status of the lymphocytes

Am J Gastroenterol

(1988)

FerrariC et al.

Functional characterization of intrahepatic, hepatitis B virus nucleo-protein-specific helper T-cell lines

J Immunol

(1987)

DienesHP et al.

Ultrastructural localization of interferon-producing cells in the livers of patients with chronic hepatitis B

Hepatology

(1991)

van den OordJJ et al.

HLA expression in liver disease

FrancoA et al.

Expression of Class I and Class II Major Histocompatibility Complex antigens on human hepatocytes

Hepatology

(1988)

SpringerTA

Adhesion receptors of the immune system

Nature

(1990)

VolpesR et al.

Immunohistochemical study of adhesion molecules in liver inflammation

Hepatology

(1990)

VolpesR et al.

Hepatic expression of intercellular adhesion molecule-1 (ICAM-1) in viral hepatitis B

Hepatology

(1990)

BiddisonWE et al.

CD4 expression and function in HLA Class II-specific T cells

Immunol Rev

(1989)

BiererBE et al.

T-lymphocyte activation: the biology and function of CD2 and CD4

Immunol Rev

(1989)

MeuerSC et al.

Human cytotoxic T cell clones directed at autologous virus transformed targets: further evidence for linkage of genetic restriction to T4 and T8 surface glycoproteins

J Immunol

(1983)

DoyleC et al.

Interaction between CD4 and class II MHC molecules mediates cell adhesion

Nature

(1987)

BenacerrafB et al.

The immune response genes of the Major Histocompatibility Complex

Immunol Rev

(1978)

EndresRO et al.

Induction of Ia antigens on nonlymphoid cells by lymphokines

Concepts Immunopathol

(1988)

SkoskiewiczMJ et al.

Wide-spread and selective induction of Major Histocompatibility Complex-determined antigens in vivo by γ interferon

J Exp Med

(1985)

van den OordJJ et al.

In-situ distribution of major histocompatibility complex products and viral antigens in chronic hepatitis B virus infection. Evidence that HBc-containing hepatocytes may express HLA DR antigens

Hepatology

(1986)

HuK-Q et al.

Trans-activation of HLA-DR gene by hepatitis B virus X gene product

RothleinR et al.

A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1

J Immunol

(1986)

DiamonMS et al.

ICAM-1 (CD54): a counter receptor for Mac-1 (CD11b/CD18)

J Cell Biol

(1990)

Cited by (45)

Scheuer’s Liver Biopsy Interpretation
2015, Scheuer's Liver Biopsy Interpretation
Down-regulation of Toll-like receptor 7 expression in hepatitis-virus- related human hepatocellular carcinoma
2013, Human Pathology
Citation Excerpt :
Recent studies suggest that some viruses may suppress host defenses by disabling aspects of the TLR signaling [22,23]. The liver is an immunocompetent organ that plays a key role in the innate immune response to pathogens [24]. The liver also produces both inflammatory mediators and acute-phase reactants and functions to remove pathogens and microbial products from the blood [25].
Toll-like receptors (TLRs) play a pivotal role in innate immunity, controlling inflammatory responses, and further development of adaptive immunity. Hepatitis virus can establish chronic infection, and the associated inflammatory responses are important determinants of virus-associated liver damage. However, the contributions of the host immune system to chronic presence of virus are not clear in patients with hepatitis virus infection. Chronic inflammatory conditions caused by persistent hepatitis virus infections and interferon (IFN)-γ-related immunopathology are known to be related to carcinogenesis. To gain insight into the role of immune modulation in the pathogenesis of hepatocellular carcinoma (HCC), we studied the expression of TLR7 in cancerous and non-cancerous liver tissue from 87 patients with HCC. Our results showed that TLR7 is significantly down-regulated in neoplastic hepatocytes (P < .001), especially in the patients with hepatitis B (n = 52) or C (n = 24) virus infection. We confirmed this decreased TLR7 expression by quantitative analysis of mRNA using real-time reverse transcription-polymerase chain reaction in 26 liver specimens of HCC patients. Using serial deletion analysis of the TLR7 promoter, a hepatocyte-specific regulatory region was found at nucleotides −156 to −98 in the TLR7 promoter. Furthermore, the effects of IFN-γ on TLR7 expression in a hepatoma cell line (HepG2) were investigated in vitro. We demonstrated that IFN-γ significantly decreased TLR7 promoter activity and expression in a dose-dependent manner. We thus propose that hepatitis virus induces down-regulation of TLR7 gene expression through IFN-γ, thereby modulating inflammatory signaling in hepatoma cells.
Mechanisms underlying the hepatotoxicity of nonsteroidal antiinflammatory drugs
2013, Drug-Induced Liver Disease
Drug-induced liver injury (DILI) induced by nonsteroidal antiinflammatory drugs (NSAIDs) is clearly idiosyncratic (i.e., host-dependent). Therefore, a discussion on mechanisms underlying the hepatic toxicity of NSAIDs includes both those that determine the compound-specific hazard and those that determine an individual’s risk to develop DILI. Significant liver injury is confined to a relatively small number of NSAIDs rather than being based on a general pharmacological class effect or chemical family effect. Insights into the compound-specific mechanisms have mostly been obtained from cell or rodent studies with the model NSAID, diclofenac, and, to a lesser extent, sulindac or nimesulide. Toxicity is multifactorial and includes toxicokinetic factors (metabolic bioactivation and disposition), as well as toxicodynamic factors (disruption of mitochondrial function, endoplasmic reticulum stress, oxidant stress, apoptosis, activation of proinflammatory pathways, and innate or adaptive immune reactions). The patient-specific mechanisms are largely unknown, but a causal association between certain HLA haplotypes and NSAID-induced DILI has been emerging. Owing to the unique sensitivity of rodents to NSAID-induced gastrointestinal injury, there are no validated animal models available. Instead, efforts should be concentrated on analyzing DILI patient-specific determinants of susceptibility.
Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice
2005, Gastroenterology
Background & Aims: Early growth response-1 (Egr-1), an immediate early gene/zinc-finger transcription factor, is required for maximal stimulation of tumor necrosis factor α (TNF-α) transcription in response to lipopolysaccharide (LPS). Because chronic ethanol exposure sensitizes macrophages to LPS-stimulated TNF-α expression, we have investigated the role of Egr-1 in mediating increased LPS-stimulated TNF-α expression after chronic ethanol feeding. Furthermore, because TNF-α contributes to alcoholic liver injury, we tested the hypothesis that Egr-1 is required for the development of ethanol-induced fatty liver injury in wild type and egr-1 −/− mice. Methods: Wild-type and egr-1 −/− mice were fed ethanol-containing diets or pair-fed control diets for 6 weeks. Results: Wild-type mice fed the ethanol diet developed hepatic steatosis characterized by micro- and macrovesicular lipid accumulation. However, egr-1 −/− mice did not develop steatosis after ethanol feeding. Alanine transferase and TNF-α concentrations in serum were increased after ethanol feeding in wild-type but not egr-1 −/− mice. In wild-type mice, challenge with LPS increased Egr-1 messenger RNA (mRNA) and DNA binding activity in liver; this response to LPS was enhanced after chronic ethanol feeding. LPS challenge also increased hepatic TNF-α mRNA and serum TNF-α to a greater extent after ethanol feeding compared with pair-fed wild-type mice. However, chronic ethanol feeding did not enhance LPS-stimulated TNF-α mRNA or serum TNF-α in egr-1 −/− mice. Conclusions: These data show that Egr-1 contributes to increased LPS-mediated TNF-α expression after chronic ethanol and that the absence of Egr-1 prevents chronic ethanol-induced fatty liver, as well as increased sensitivity to LPS.
Neuroendocrinology of insulin resistance: Metabolic and endocrine aspects of adiposity
2003, European Journal of Pharmacology
Abdominal obesity is a major risk factor to attract the insulin resistance syndrome. It is proposed that abdominal obesity exposes the liver to elevated levels of free fatty acids, which activate a neuroendocrine reflex, leading to increased circulating levels of glucocorticoids. Besides directly attenuating peripheral insulin signaling, glucocorticoids oppose the activity of central nervous regulatory systems that stimulate insulin action. Among the factors that promote insulin action is leptin. Leptin regulates peripheral fuel partitioning and insulin action mainly through hypothalamic neuronal networks, which in turn, regulate endocrine activity of adipose tissue in a way comparable to thiazolidinediones. These are a class of insulin-sensitizing drugs, which exert their antidiabetic effects through the gamma isoform of peroxisome proliferator-activated receptor (PPAR-γ). Since glucocorticoids oppose leptin action at several levels of control (including the central nervous system, CNS), it is argued that subjects easily develop obesity and associated metabolic disorders.
LFA-1/ICAM-1 interaction is essentially involved in the pathogenesis of delayed-type hypersensitivity-induced liver injury to picryl chloride
1998, Life Sciences
The kinetics of lymphocyte function associated antigen 1 (LFA-1) expression on spleen cells (SPC) and liver non-parenchymal cells (NPC), and intercellular adhesion molecule 1 (ICAM-1) expression on hepatocytes (HC) was examined in acute liver injury mice induced by a DTH reaction to picryl chloride (PCl). The peak expression of LFA-1 on SPC was seen at 6 hr after eliciting liver injury, and then that of LFA-1 on NPC and ICAM-1 on HC appeared at 12 hr. Thereafter, the serum ALT elevation reached to a peak at 18 hr. A splenectomy before the PCl elicitation significantly reduced the ALT elevation. Both SPC and NPC from liver injury mice induced a remarkable release of ALT from HC in vitro, in parallel with their LFA-1 expression. The pre-treatment of NPC or SPC with anti-LFA-1 mAb, irrespective of the presence of complement, completely blocked the ALT release. Also, when HC was prebound with anti-ICAM-1 mAb, neither NPC nor SPC showed a cytotoxicity against the HC. Furthermore, the treatment of NPC with either anti-Thy1.2 or anti-CD4 mAb in the presence but not absence of complement, showed a complete abolishment of ALT release. Anti-CD8 mAb plus complement also tended to inhibit ALT release. The twofold increase in CD4⁺ LFA-1⁺ and mild increase in CD8⁺ LFA-1⁺ populations were also confirmed in NPC at 12 hr. These results suggest that PCl elicitation in liver may trigger an increased expression of LFA-1 on SPC and NPC and ICAM-1 on HC. LFA-1/ICAM-1 interaction between liver-infiltrating NPC, mainly including CD4⁺ and CD8⁺ T cells, and HC may be an essential step for the hepatocyte damage in PCl-DTH liver injury.

View all citing articles on Scopus

^*: Dr. Riccardo Volpes is temporarily on leave from the Clinica Medica R, Ospedale V. Cervello, Palermo, Italy.

View full text

ReviewCan hepatocytes serve as ‘activated’ immunomodulating cells in the immune response?

Immunol Today

Lancet

Gastroenterology

Immunol Today

Immunol Today

Gastroenterology

Lancet

Hum Immunol

J Hepatol

Cell

Cell

Immunol Today

J Invest Dermatol

J Am Acad Dermatol

J Neuroimmunol

J Biol Chem

J Invest Dermatol

J Invest Dermatol

Immunol Today

Antigen presentation at the inflammatory site

Crit Rev Immunol

The basis for the immunoregulatory role of macrophages and other accessory cells

Science

Accessory cell signals involved in T-cell activation

Immunol Rev

Lymphoid dendritic cells

Immunology

Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells

Nature

Immunopathology of chronic hepatitis

Immunopathology of chronic viral hepatitis

Hepato-Gastroenterology

Studies of lymphocyte subpopulations in the liver tissue and blood of patients with chronic active hepatitis

J Clin Immunol

An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease

Hepatology

Cellular and humoral immune reactions in chronic active liver disease. II. Lymphocyte subsets and viral antigens in liver biopsies of patients with acute and chronic hepatitis B

Clin Exp Immunol

Memory T cells represent the predominant lymphocyte subset in acute and chronic liver inflammation

Hepatology

Human memory T-lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2 and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production

J Immunol

Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic Type B hepatitis, with special emphasis on the activation status of the lymphocytes

Am J Gastroenterol

Functional characterization of intrahepatic, hepatitis B virus nucleo-protein-specific helper T-cell lines

J Immunol

Ultrastructural localization of interferon-producing cells in the livers of patients with chronic hepatitis B

Hepatology

HLA expression in liver disease

Expression of Class I and Class II Major Histocompatibility Complex antigens on human hepatocytes

Hepatology

Adhesion receptors of the immune system

Nature

Immunohistochemical study of adhesion molecules in liver inflammation

Hepatology

Hepatic expression of intercellular adhesion molecule-1 (ICAM-1) in viral hepatitis B

Hepatology

CD4 expression and function in HLA Class II-specific T cells

Immunol Rev

T-lymphocyte activation: the biology and function of CD2 and CD4

Immunol Rev

Human cytotoxic T cell clones directed at autologous virus transformed targets: further evidence for linkage of genetic restriction to T4 and T8 surface glycoproteins

J Immunol

Interaction between CD4 and class II MHC molecules mediates cell adhesion

Nature

The immune response genes of the Major Histocompatibility Complex

Immunol Rev

Induction of Ia antigens on nonlymphoid cells by lymphokines

Concepts Immunopathol

Wide-spread and selective induction of Major Histocompatibility Complex-determined antigens in vivo by γ interferon

J Exp Med

In-situ distribution of major histocompatibility complex products and viral antigens in chronic hepatitis B virus infection. Evidence that HBc-containing hepatocytes may express HLA DR antigens

Hepatology

Trans-activation of HLA-DR gene by hepatitis B virus X gene product

A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1

J Immunol

ICAM-1 (CD54): a counter receptor for Mac-1 (CD11b/CD18)

J Cell Biol

Review
Can hepatocytes serve as ‘activated’ immunomodulating cells in the immune response?